Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC

Roche has secured approval from the US Food and Drug Administration (FDA) for its Tecentriq (atezolizumab) plus chemotherapy for the initial treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).